Practical Considerations in theTreatment of Psoriasis with Biologics

A supplement to Skin & Allergy News. Supported by unrestricted educational grants from Centocor Inc. and Genentech. This supplement was jointly sponsored by the Elsevier Office of Continuing Medical Education and Skin & Allergy News. The presentations in this supplement were made at a continuing medical education satellite symposium that was jointly sponsored by the Skin Disease Education Foundation and the Elsevier Office on Continuing Medical Education, held on August 2, 2007, in New York, N.Y.

• Contents
•Target Audience
•Needs Assessment
•Educational Objectives
•Accreditation

To view the supplement, click the image above.

Contents

Introduction
David M. Pariser, MD, Chair
Professor, Department of Dermatology
Eastern Virginia Medical School
Norfolk, Va.
Dr. Pariser has received funding for clinical grants from and is a consultant to and an investigator for Abbott, Amgen, Centocor, and Genentech. He will discuss the unlabeled use of adalimumab, etanercept, infliximab, and efalizumab.

The Practical Use of Infliximab in the Office: As-Observed Data From One Dermatologist's Experience
Craig L. Leonardi, MD
Associate Clinical Professor of Dermatology
St. Louis University Medical School and Central Dermatology
St. Louis, Mo.
Dr. Leonardi has received honoraria from and is a consultant to Abbott, Amgen, Bristol-Myers Squibb Company, Centocor, CombinatoRx, Genentech, and Warner Chilcott. He is also an investigator for 3M Pharmaceuticals, Abbott, Allergan, Altana, Amgen, Astellas, Centocor, Galderma Laboratories, Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, and Vitae.

Etanercept: Efficacy and Safety of Twice-Weekly, 50-mg Dosing
Alexa Boer Kimball, MD, MPH
Assistant Professor
Harvard Medical School, Massachusetts
General and Brigham and Women's Hospital
Boston, Mass.
Dr. Kimball has received funding for clinical grants from and is a consultant to Amgen, Inc.

Adalimumab: A Practical Approach to Psoriatic Disease
Bruce E. Strober, MD, PhD
Assistant Professor
Ronald O. Perelman Department of Dermatology
New York University School of Medicine
New York, N.Y.
Dr. Strober has received funding for clinical grants and honoraria from Abbott, Amgen, Astellas, Centocor, and Genentech. He will discuss the unlabeled use of adalimumab.

Alefacept: Patient Selection and Treatment Expectations
Neil J. Korman, MD, PhD
Professor of Dermatology
Case Western University
Cleveland, Ohio
Dr. Korman has received funding for clinical grants from, is a consultant to, and has received honoraria from Abbott Laboratories, Amgen, Astellas, Centocor, and Genentech. He will discuss unlabeled use of adalimumab.

Efalizumab: Optimal Use in Patients With Psoriasis
Jeffrey M. Sobell, MD
Assistant Professor of Dermatology
Tufts University School of Medicine
Boston, Mass.
Dr. Sobell has received funding for clinical grants from, is a consultant to, and has received honoraria from Abbott, Amgen, Centocor, and Genentech.

Target Audience

This activity is designed for dermatologists and other healthcare providers who manage patients with psoriasis.
Needs Assessment

Approximately 1.5 million people in the United States suffer with moderate to severe psoriasis. According to dermatology opinion leaders, all of these patients qualify for systemic therapy, yet only one third are being treated. Although biologic therapies represent a significant safety advance over conventional systemic therapies, such as methotrexate and cyclosporine, most of the patients receiving systemic agents are not being treated with biologics; therefore, this patient population is greatly underserved.

Clinicians need to remain up-to-date on the most recent therapies for the patient with psoriasis. This multi-sponsored educational activity will review developments in the use of biologics in the treatment of psoriasis. It will provide dermatologists with practical clinical information that is immediately useful in the care of their patients.
Educational Objectives

After reading this supplement, clinicians should be able to:
• Discuss the basic science and real-world use of the biologic agents in the management of psoriasis
• Evaluate the long-term safety and efficacy of biologic agents in the treatment of psoriasis
• Describe to patients what expectations are realistic regarding biologic treatment of psoriasis
• Explain the role of screening for infectious diseases prior to initiation of certain biologic agents.
Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Elsevier Office of Continuing Medical Education (EOCME), Skin & Allergy News, and Skin Disease Education Foundation. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.

The EOCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit

---